Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Tian Z, Shi C, Yang G, Allen JK, et al. Leukemia 2023;37:2006-2016.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tian Z, Shi C, Yang G, Allen JK, et al. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia 2023;37:2006-2016.
PMID: 37634013